Manufacturing News
Boehringer Ingelheim Partners with Simcere on Pre-Clinical IBD Asset
Boehringer Ingelheim and Simcere Pharmaceutical Group have signed a licence and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL-23p19 bispecific antibody, for the treatment of inflammatory bowel disease (IBD). The partnership aims to advance the candidate through global development. SIM0709
28 January 2026